Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific ...
Spectral Capital Corporation ("Spectral" or the "Company") today announced 2026 revenue guidance of $450,000,000, up from the 2025 $274,000,000 combined revenue guidance as a result of its pending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback